Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.775
Bid: 9.75
Ask: 9.80
Change: 0.00 (0.00%)
Spread: 0.05 (0.513%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.775
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)

12 Dec 2018 13:01

Edison Investment Research Limited Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX) 12-Dec-2018 / 13:01 GMT/BST


London, UK, 12 December 2018

Edison issues outlook on e-Therapeutics (ETX)

e-Therapeutics (ETX) has announced a long-awaited research collaboration with Novo Nordisk (Novo) on early target discovery in diabetes. This is the first commercial collaboration in ETX's history and will last for at least a year. The financial terms of the transaction were not disclosed but the deal should be recognised for its validation of ETX's disease-aware network-driven drug discovery (NDD) platform. This is expected to be the first in an expected series of deals on the NDD platform and the assets generated from it.

We have maintained our previous valuation at £63.5m or 24p per share and will review the impact of the transaction on ETX's cash position at the FY19 results. We continue to expect more than one such transaction although the timing is uncertain.Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitewww.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Andy Smith, +44 (0)20 3077 5700healthcare@edisongroup.comLearn more at www.edisongroup.com and connect with Edison on:LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_ResYouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

757183 12-Dec-2018 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
20th Jun 20144:22 pmRNSHolding(s) in Company
20th Jun 20141:41 pmRNSHolding(s) in Company
18th Jun 20146:14 pmRNSAdditional Listing
30th May 20147:00 amRNSAnnual Financial Report and Notice of AGM
22nd May 20144:15 pmRNSIssue of Equity
12th May 20147:00 amRNSFull year results
8th May 20147:00 amBUSe-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial
2nd May 20144:46 pmRNSHolding(s) in Company
2nd May 20144:42 pmRNSHolding(s) in Company
2nd May 20144:29 pmRNSHolding(s) in Company
25th Apr 20147:00 amRNSNotice of Results
7th Apr 20141:07 pmRNSDirectorate Change
7th Apr 201411:46 amRNSDirectorate Change
31st Mar 20146:56 amBUSe-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours
26th Mar 20147:00 amBUSe-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial
10th Feb 20147:02 amBUSe-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers
24th Jan 20147:00 amBUSTemporary halt of recruitment into ETS2101 cancer trials because of drug supply issue - Patients already being treated will continue to be dosed
9th Jan 20142:34 pmRNSAdditional Listing
7th Jan 20147:00 amBUSStatement re e-Therapeutics provides update on ETS2101 phase I trial in brain cancer
31st Oct 20137:00 amBUSResearch Update
16th Oct 20137:00 amBUSHalf-yearly Report
30th Sep 20134:45 pmRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSNotice of Interim Results
6th Aug 201312:43 pmRNSAdditional Listing
1st Aug 20134:53 pmRNSDirector/PDMR Shareholding
30th Jul 20133:30 pmRNSDirector/PDMR Shareholding
25th Jul 201311:09 amRNSResult of AGM
24th Jul 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20134:41 pmRNSDirector/PDMR Shareholding
1st Jul 20139:00 amRNSNotice of AGM and Annual Report
21st Jun 20137:00 amRNSProactive Investors One2One Forum 26th Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
14th May 20137:00 amBUSPreliminary results for the year ended 31 January 2013
18th Apr 20137:00 amRNSNotice of Results
4th Apr 20135:18 pmRNSDirector/PDMR Shareholding
25th Mar 201310:44 amRNSHolding(s) in Company
18th Mar 20135:19 pmRNSIssue of Equity
13th Mar 20136:19 pmRNSHolding(s) in Company
6th Mar 201310:01 amRNSHolding(s) in Company
5th Mar 20135:44 pmRNSHolding(s) in Company
4th Mar 20133:31 pmRNSHolding(s) in Company
4th Mar 20133:23 pmRNSDirector/PDMR Shareholding
4th Mar 20132:56 pmRNSHolding(s) in Company
1st Mar 20137:00 amRNSCompletion of the Placings
28th Feb 201312:01 pmRNSCompletion of First Placing / Issue of Equity
27th Feb 201310:01 amRNSResult of General Meeting / Issue of Equity
22nd Feb 20132:51 pmRNSDirector/PDMR Shareholding
19th Feb 20139:45 amRNSDirector/PDMR Shareholding
15th Feb 20132:27 pmRNSDirector/PDMR Shareholding
14th Feb 20137:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.